Eagle Pharmaceuticals Inc (NASDAQ:EGRX) — Market Cap & Net Worth
Market Cap & Net Worth: Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has a market capitalization of $3.29 Million ($3.29 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29327 globally and #5927 in its home market, demonstrating a 2.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eagle Pharmaceuticals Inc's stock price $0.62 by its total outstanding shares 13157553 (13.16 Million). Review total liabilities of Eagle Pharmaceuticals Inc to assess the company's total debt and financial obligations.
Eagle Pharmaceuticals Inc Market Cap History: 2025 to 2026
Eagle Pharmaceuticals Inc's market capitalization history from 2025 to 2026. Data shows growth from $4.47 Million to $8.09 Million (0.00% CAGR).
Eagle Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eagle Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EGRX by Market Capitalization
Companies near Eagle Pharmaceuticals Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Eagle Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Eagle Pharmaceuticals Inc Historical Marketcap From 2025 to 2026
Between 2025 and today, Eagle Pharmaceuticals Inc's market cap moved from $4.47 Million to $ 8.09 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.09 Million | +80.88% |
| 2025 | $4.47 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Eagle Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.29 Million USD |
| MoneyControl | $3.29 Million USD |
| MarketWatch | $3.29 Million USD |
| marketcap.company | $3.29 Million USD |
| Reuters | $3.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more